- Home
- AMLX
as 11-15-2024 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 481.9M | IPO Year: | 2022 |
| Target Price: | $6.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $19.95 | Next Earning Date: | 11-07-2024 |
| Revenue: | $196,485,000 | Revenue Growth: | -33.22% |
| Revenue Growth (this year): | -76.53% | Revenue Growth (next year): | 149.49% |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Sep 30 '24 | Sell | $3.20 | 18,589 | $59,414.16 | 3,220,569 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Sep 30 '24 | Sell | $3.20 | 8,709 | $27,840.06 | 142,768 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Sep 30 '24 | Sell | $3.20 | 18,589 | $59,429.03 | 3,120,569 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Sep 30 '24 | Sell | $3.20 | 11,442 | $36,559.48 | 143,801 | |
| FRATES JAMES M | AMLX | Chief Financial Officer | Sep 12 '24 | Buy | $2.53 | 40,000 | $101,368.00 | 233,464 | |
| Firestone Karen | AMLX | Director | Sep 5 '24 | Buy | $2.13 | 50,000 | $106,590.00 | 55,000 | |
| MILNE GEORGE M JR | AMLX | Director | Sep 3 '24 | Buy | $2.20 | 100,000 | $219,800.00 | 858,571 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)
GuruFocus.com
9 days ago
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Thomson Reuters StreetEvents
9 days ago
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call
Business Wire
10 days ago
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Business Wire
13 days ago
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
GuruFocus.com
23 days ago
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc
MT Newswires
25 days ago
Amylyx Pharmaceuticals Shares Rise After BofA Upgrade
MT Newswires
25 days ago
BofA Securities Upgrades Amylyx Pharmaceuticals to Buy From Neutral, Price Target is $10
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.